Tashatuvango / shutterstock.com
Japanese pharmaceutical company Astellas has filed a complaint against another Japanese company, Sawai Pharmaceutical, for allegedly infringing its patents centring on the drug Myrbetriq (mirabegron).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Astellas, Sawai, Myrbetriq, patent, ANDA, FDA